However, CRISPR/Cas9 also enhances the sensitivity of cancer cells to chemotherapy, modulates their ability to release cytotoxic substances through precise PD-L1 targeting, and improves their resistance to tumor chemotherapy, as well as amplifies the therapeutic effect of chemoradiotherapy. Here, CD274 is linked to cancer.